PSTV · Plus Therapeutics, Inc.
$3.92
+0.09 (+2.35%)
At close · Jul 21
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$26.98M
Shares
6.88M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Marc H. Hedrick | CEO | $954,651 |
| Norman LaFrance | Chief Medical Officer | $637,811 |
| Andrew Sims | CFO | $446,176 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Marc H. Hedrick | CEO | $1,667,279 |
| Andrew Sims | CFO | $845,091 |
| Norman LaFrance | Chief Medical Officer | $292,704 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Marc H. Hedrick | CEO | $1,132,430 |
| Andrew Sims | CFO | $412,953 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Marc H. Hedrick | CEO | $867,428 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Marc H. Hedrick | CEO | $614,978 |